Gastroesophageal Cancers at ASCO 2024

CME

Redefining the Possibilities for Patients With HER2-positive Gastroesophageal Cancers

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 13, 2024

Expiration: June 12, 2025

Jaffer Ajani
Jaffer Ajani, MD
Nataliya Uboha
Nataliya Uboha, MD, PhD
Zev A. Wainberg
Zev A. Wainberg, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is the appropriate PD-L1 CPS cutoff to be eligible for first-line pembrolizumab + trastuzumab/CT?

2.

  • 64-yr-old man, previously very healthy

  • Diagnosed with GEJ adenocarcinoma with extensive liver and nodal mets, HER2+, PD-L1+, MS stable

  • Good response to 1L oxaliplatin/FU/trastuzumab but after 18 mo, cancer progressing in liver

Which of the following 2L treatment options would you recommend for this patient?

3.

  • 64-yr-old man with HER2+ metastatic GEJ adenocarcinoma

  • Received 20 doses of 2L T-DXd before developing grade 3 ILD

In addition to maximizing supportive care, which of the following management strategies would you recommend for this patient with grade 3 ILD?